The Living Quality Infection of Combined Chemotherapy of Domestic Paclitaxel and Carboplatin for the Patients with Advanced Non-small Cell Lung Cancer and their Age was Up-ward 60 Years

Objective 　To discuss the living quality infection of combined chemotherapy of domestic paclitaxel and carboplatin for the patients with advanced non-small cell lung cancer (NSCLC) and their age was upward 60 years. Methods 　78 cases the aged patient with advanced non-small cell lung cancer were randomly divided into two groups, and were respectively t reated with CT-regimen ( domestic paclitaxel of making in our country and carboplatin) and CE-regimen (etoposide and carboplatin) . And to observed and compared recent effect and living quality. Results 　The impersonality effect (47. 50 %), median remissive time (8 moths), median survival time (11 moths), pathological headway time (6 moths), one year subsistence rate (30 %) and clinical benefit response (masculine rate of action estate 52. 50 %, masculine rate of avoirdupois 40 %) of CT-regimen were higher than that of CE-regimen ( 23. 68 %, 4 moths, 7 moths, 4 moths, 13. 16 %, 28. 9 %, 13. 2 %), there were evidently difference ( P < 0. 05 or 0. 01), but the side-effect of two groups was not evidently difference ( P > 0. 05) . The two treatment regimen all could significantly improve the recent living quality of the aged patients with advanced NSCLC, but af ter treatment 1 and 4 moths, the QOL grades of CT-regimen was excelled than that of CE-regimen, and there were significant difference ( P < 0. 05) . Conclusion 　The effect of CT-regimen (domestic paclitaxel of making in our count ry and carboplatin) was significantly excelled that of CE-regimen (etoposide and carboplatin) in treating the patient s with advanced NSCLC and their age was upward 60 years. And the CT-regimen can better increase their living quality and clinical benefit response.